- Home
- NUVB vs MYI Comparison
NUVB vs MYI Comparison
Compare NUVB & MYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVB
- MYI
- Stock Information
- Founded
- NUVB 2018
- MYI 1992
- Country
- NUVB United States
- MYI United States
- Employees
- NUVB N/A
- MYI N/A
- Industry
- NUVB Biotechnology: Pharmaceutical Preparations
- MYI Investment Bankers/Brokers/Service
- Sector
- NUVB Health Care
- MYI Finance
- Exchange
- NUVB Nasdaq
- MYI Nasdaq
- Market Cap
- NUVB 850.3M
- MYI 794.9M
- IPO Year
- NUVB N/A
- MYI N/A
- Fundamental
- Price
- NUVB $2.62
- MYI $11.33
- Analyst Decision
- NUVB Strong Buy
- MYI
- Analyst Count
- NUVB 6
- MYI 0
- Target Price
- NUVB $6.17
- MYI N/A
- AVG Volume (30 Days)
- NUVB 2.1M
- MYI 256.7K
- Earning Date
- NUVB 11-06-2024
- MYI 01-01-0001
- Dividend Yield
- NUVB N/A
- MYI 4.81%
- EPS Growth
- NUVB N/A
- MYI N/A
- EPS
- NUVB N/A
- MYI N/A
- Revenue
- NUVB $2,162,000.00
- MYI N/A
- Revenue This Year
- NUVB N/A
- MYI N/A
- Revenue Next Year
- NUVB N/A
- MYI N/A
- P/E Ratio
- NUVB N/A
- MYI N/A
- Revenue Growth
- NUVB N/A
- MYI N/A
- 52 Week Low
- NUVB $1.22
- MYI $9.32
- 52 Week High
- NUVB $4.16
- MYI $11.70
- Technical
- Relative Strength Index (RSI)
- NUVB 49.69
- MYI 44.74
- Support Level
- NUVB $2.44
- MYI $11.28
- Resistance Level
- NUVB $3.07
- MYI $11.41
- Average True Range (ATR)
- NUVB 0.17
- MYI 0.09
- MACD
- NUVB -0.01
- MYI 0.02
- Stochastic Oscillator
- NUVB 43.26
- MYI 62.16
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
About MYI Blackrock MuniYield Quality Fund III Inc
BLACKROCK MUNIYIELD QUALITY FUND III, INC. is a diversified, closed-ended investment management company. Its investment objective is to provide shareholders with a high level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in various sectors such as Transportation; Utilities; Health; Education; Tobacco and others.